BioSpace News Archive

Sequana Medical NV announces that data from the Roll-In Cohort of POSEIDON1, its North American pivotal alfapump study, have been selected for a poster presentation at the American Association for the Study of Liver Diseases The Liver Meeting, taking place in Washington, DC from 4 to 8 November 2022.

Calliditas Therapeutics AB publishes the nomination committee’s composition for the AGM in 2023.

Lannett Company, Inc. announced that it has received approval from the US Food and Drug Administration to manufacture Numbrino®, the company’s branded topical anesthetic product, at its main plant in Seymour, Indiana.

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that data from its landmark ReOpen phase 3 clinical trial program will be presented at IDWeek 2022 in Washington, D.C. today.

Matinas BioPharma announced today that Jerome D. Jabbour, Chief Executive Officer of Matinas BioPharma, will present at the ThinkEquity Investment Conference on Wednesday, October 26, 2022, at 10:30 a.m. ET, and host investor meetings.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for EYLEA ® (aflibercept) Injection.

U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for CAMZYOS ® (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction Therapy.

Spectrum Pharmaceuticals, Inc. today announced the commercial availability of ROLVEDON™ (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.

Matinas BioPharma Holdings, Inc. today announced positive interim data from Cohort 4, the fourth and final cohort of the Phase 2 EnACT trial evaluating MAT2203, an oral LNC formulation of amphotericin B, for the treatment of cryptococcal meningitis.

NightHawk Biosciences announced that its Scorpion subsidiary plans to host the grand opening of its San Antonio facility today, October 21.